No fresh guidelines on Covid, no panic, say health officials
Covid-19 guidelines
or protocols at present.
Officials received instructions to maintain calm and avoid causing unnecessary alarm regarding the recent Covid-19 cases reported within the state.
Officials confirmed that the Covid-19-related fatality recorded in Jaipur on Sunday was an isolated incident, linked to co-morbidity, tuberculosis.
In this regard,
Health minister Gajendra Singh Khimsar
held a meeting with health department officials on Tuesday to provide necessary directions.
Khimsar said that according to the Centre, the
current variant of Covid-19
circulating in the country is not lethal, but people should take basic precautions and seek necessary advice, testing, and treatment at medical institutions if they exhibit symptoms like cough, cold, or fever.
Khimsar emphasised that vulnerable groups including elderly, pregnant women, and children should take special care of their health in light of the Covid-19 cases.
If symptoms of influenza-like illness (ILI) appear, they should consult a doctor and avoid crowded places. He instructed officials that although medical experts have not indicated a significant threat from Covid-19 under current circumstances, medical institutions should be prepared with necessary arrangements.
Principal secretary (health) Gayatri Rathore directed the officials to ensure that oxygen plants remain operational and instructed that regular monitoring of oxygen plants established in various medical institutions across the state should be conducted.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
an hour ago
- Time of India
Gitam institute of medical sciences and research to organise CME on genes, morphology on August 22
Visakhapatnam: The department of anatomy at Gitam institute of medical sciences and research (GIMSR) will organise a programme on continuing medical education (CME) titled 'genes, morphology, and malformations' on August 22. According to head of the department (HoD) Dr Padmini, the CME is designed to enhance knowledge of healthcare professionals in the clinical application of human genetics, with a focus on diagnostic accuracy, ethical decision making and patient centered care. "Participants will gain an in-depth understanding of DNA structure, gene expression, and chromosomal organization essential foundations for interpreting genetic data in clinical practice. The programme will also cover the diagnosis of common genetic and chromosomal disorders such as Down syndrome, cystic fibrosis, and BRCA-related cancers. By integrating genetic principles with real-world clinical scenarios, the event aims to improve diagnostic skills and promote more personalized, patient-focused treatment strategies." "Additionally, the CME will provide hands on training in interpreting genetic test results, with emphasis on understanding their indications, limitations, and clinical relevance. Interested healthcare professionals are requested to register by submitting their details on or before August 1. For more information and registration details, please contact the department of anatomy, GIMSR," Dr Padmini added. Get the latest lifestyle updates on Times of India, along with Friendship Day wishes , messages and quotes !
Economic Times
13 hours ago
- Economic Times
Cancer cure? Russia commences human trials of revolutionary personalized cancer vaccine
In a landmark advancement for oncology and personalized medicine, Russia's Gamaleya National Research Center of Epidemiology and Microbiology—the creators of the Sputnik V COVID-19 vaccine—announced this year that it will begin human clinical trials of the world's first personalized mRNA-based melanoma vaccine within the next few months. Alexander Gintsburg, director of the Gamaleya Center, confirmed that this groundbreaking vaccine, tailored specifically to the genetic profile of individual patients' tumors, will start experimental administration as early as September-October 2025 in collaboration with leading Russian oncology institutions. Q. What are melanoma cellsA. Melanoma cells come from melanocytes, the skin cells that give it color. When these cells grow too much and become cancerous, they cause melanoma, a dangerous kind of skin cancer that can spread fast if not treated early. Q. What is mRNA, and how is it used in vaccines? A. mRNA, or messenger RNA, is a molecule that carries genetic instructions from DNA to the cell's protein-making machinery. It acts like a messenger, conveying the code needed to build specific proteins that perform various functions in the body. In vaccines, mRNA teaches cells to produce a harmless piece of a virus or cancer antigen, triggering the immune system to respond and protect the body. This novel cancer vaccine is designed to train the immune system to recognize and attack melanoma cells by creating a bespoke mRNA blueprint derived from each patient's unique tumor mutations. The process involves sophisticated artificial intelligence algorithms that analyze the tumor's genetic data to produce a molecular template, which is then synthesized at Gamaleya's production facilities. This tailor-made mRNA encodes proteins that activate a targeted cytotoxic immune response, aiming not only to eradicate primary tumors but also to address metastatic cancer elaborated that the entire vaccine development cycle—from tumor sequencing to vaccine production—can be completed within about one week due to AI-assisted mathematical modeling and neural network computing. This rapid manufacture represents a significant leap compared to typical timelines in personalized cancer therapies. Q. What is a personalized cancer vaccine?A. Personalized cancer vaccine is a tailored immunotherapy designed to train the patient's immune system to recognize and attack their specific cancer cells. It uses information from the patient's tumor genetics to create a unique vaccine that targets tumor-specific mutations, differing from general vaccine model was developed starting in mid-2022 and has already demonstrated promising efficacy in preclinical animal studies, showing the ability to suppress tumor growth and reduce metastasis. The upcoming Phase I clinical trials will take place at two of Russia's foremost oncology centers: the Hertsen Research Institute and the N.N. Blokhin National Medical Research Center of Oncology in Moscow. Importantly, this tailored vaccine is part of a wider Russian initiative to advance cancer treatment across various difficult-to-treat types, including pancreatic, kidney, and non-small-cell lung cancers. The Russian Ministry of Health classifies this vaccine development and approval under a new, specialized regulatory process recognizing its individualized nature, differing fundamentally from traditional drug registration. The state plans to provide this cancer vaccine free of charge to Russian citizens, with an estimated production cost of around 300,000 rubles (approx. USD 2,869) per dose covered by government to health authorities, about 4 million Russians live with cancer, and approximately 625,000 new cancer cases are diagnosed annually, underlining the urgent need for innovative therapies. The vaccine's success could mark a pivotal moment in Russia's fight against cancer and elevate its personalized medicine the COVID-19 mRNA vaccines designed to target a single viral antigen, this personalized cancer vaccine encodes multiple neoantigens specific to each patient's tumor, offering a multi-targeted immune approach.
Time of India
13 hours ago
- Time of India
Cancer cure? Russia commences human trials of revolutionary personalized cancer vaccine
In a landmark advancement for oncology and personalized medicine, Russia's Gamaleya National Research Center of Epidemiology and Microbiology—the creators of the Sputnik V COVID-19 vaccine—announced this year that it will begin human clinical trials of the world's first personalized mRNA-based melanoma vaccine within the next few months. Alexander Gintsburg, director of the Gamaleya Center, confirmed that this groundbreaking vaccine, tailored specifically to the genetic profile of individual patients' tumors, will start experimental administration as early as September-October 2025 in collaboration with leading Russian oncology institutions . Explore courses from Top Institutes in Please select course: Select a Course Category Cybersecurity CXO others Public Policy Healthcare Digital Marketing Degree MBA Artificial Intelligence Others PGDM Data Science Data Analytics Product Management MCA Operations Management Leadership Design Thinking Project Management Finance Management healthcare Technology Data Science Skills you'll gain: Duration: 10 Months MIT xPRO CERT-MIT xPRO PGC in Cybersecurity Starts on undefined Get Details Q. What are melanoma cells by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like 15 most beautiful women in the world Undo A. Melanoma cells come from melanocytes, the skin cells that give it color. When these cells grow too much and become cancerous, they cause melanoma, a dangerous kind of skin cancer that can spread fast if not treated early. Q. What is mRNA, and how is it used in vaccines? A. mRNA, or messenger RNA, is a molecule that carries genetic instructions from DNA to the cell's protein-making machinery. It acts like a messenger, conveying the code needed to build specific proteins that perform various functions in the body. In vaccines, mRNA teaches cells to produce a harmless piece of a virus or cancer antigen, triggering the immune system to respond and protect the body. Live Events This novel cancer vaccine is designed to train the immune system to recognize and attack melanoma cells by creating a bespoke mRNA blueprint derived from each patient's unique tumor mutations. The process involves sophisticated artificial intelligence algorithms that analyze the tumor's genetic data to produce a molecular template, which is then synthesized at Gamaleya's production facilities. This tailor-made mRNA encodes proteins that activate a targeted cytotoxic immune response, aiming not only to eradicate primary tumors but also to address metastatic cancer sites. Gintsburg elaborated that the entire vaccine development cycle—from tumor sequencing to vaccine production—can be completed within about one week due to AI-assisted mathematical modeling and neural network computing. This rapid manufacture represents a significant leap compared to typical timelines in personalized cancer therapies. Q. What is a personalized cancer vaccine? A. Personalized cancer vaccine is a tailored immunotherapy designed to train the patient's immune system to recognize and attack their specific cancer cells. It uses information from the patient's tumor genetics to create a unique vaccine that targets tumor-specific mutations, differing from general vaccines. The vaccine model was developed starting in mid-2022 and has already demonstrated promising efficacy in preclinical animal studies, showing the ability to suppress tumor growth and reduce metastasis. The upcoming Phase I clinical trials will take place at two of Russia's foremost oncology centers: the Hertsen Research Institute and the N.N. Blokhin National Medical Research Center of Oncology in Moscow. Importantly, this tailored vaccine is part of a wider Russian initiative to advance cancer treatment across various difficult-to-treat types, including pancreatic, kidney, and non-small-cell lung cancers. The Russian Ministry of Health classifies this vaccine development and approval under a new, specialized regulatory process recognizing its individualized nature, differing fundamentally from traditional drug registration. The state plans to provide this cancer vaccine free of charge to Russian citizens, with an estimated production cost of around 300,000 rubles (approx. USD 2,869) per dose covered by government funding. According to health authorities, about 4 million Russians live with cancer, and approximately 625,000 new cancer cases are diagnosed annually, underlining the urgent need for innovative therapies. The vaccine's success could mark a pivotal moment in Russia's fight against cancer and elevate its personalized medicine program. Unlike the COVID-19 mRNA vaccines designed to target a single viral antigen, this personalized cancer vaccine encodes multiple neoantigens specific to each patient's tumor, offering a multi-targeted immune approach.
